The evolving treatment landscape for BRAFm anaplastic thyroid cancer
Mark Zafereo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of current treatment options for patients with BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC). Although the current standard of care has been dabrafenib and trametinib since the Phase II ROAR study (NCT02034110), a promising triplet combination of pembrolizumab with dabrafenib and trametinib (DTP) is in a Phase II trial (NCT04675710) to enable surgery and improve outcomes in this aggressive form of thyroid cancer. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
